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CD4+ T cells are classically thought to orchestrate adaptive immune re-
sponses. But recent studies demonstrate that they can also kill infected cells 
directly. A new paper shows that highly effi  cient processing of Epstein Barr 
virus (EBV) glycoproteins for presentation on MHC class II makes virus-
transformed B cells susceptible to lysis by CD4+ T cells. Thus, antiviral vac-
cines should aim to stimulate both helper and cytolytic CD4+ T cells.
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The immune system preserves the in-
tegrity of its host by recognizing and 
resisting invaders. Therefore, evolution 
has provided each species with the ca-
pacity to resist the pathogenic chal-
lenges in its ecological niche. The 
functions of diff  erent species’ immune 
systems, tailored to meet these chal-
lenges, are therefore best explored by 
investigating host resistance to patho-
gens threatening the survival of that 
species. Examples of such pathogens are 
γ-herpesviruses, which include viruses 
that infect the majority of the human 
population and threaten host survival 
by their oncogenic capacity. In this 
commentary, we discuss recent evi-
dence from studies of γ-herpes  viruses 
that CD4+ T cells not only orchestrate 
adaptive immune responses in mice and 
man, but also have mechanisms to tar-
get infected cells directly.
CD4+ T cells are essential in the control 
of herpesvirus infections
Studies of mouse γ-herpesvirus 68 
(MHV-68) have shown that CD4+ T 
cells can control a herpesvirus infection 
and its malignant consequences in vivo, 
independent of CD8+ T cells and B 
cells. MHV-68 establishes asymptom-
atic chronic infection in mice after re-
spiratory challenge due to an immune 
response that contains but does not 
eliminate the virus. Immune control of 
MHV-68 infection can be established in 
the absence of CD8+ T cells, but deple-
tion of both CD4+ and CD8+ T cells 
leads to a fatal primary infection (1). 
Depletion of CD8+ T cells resulted in 
higher virus loads in lung and spleen, 
suggesting that CD4+ T cells were more 
effi   cient at controlling MHV-68 infec-
tion in the presence of CD8+ T cells.
In addition to causing chronic infec-
tions, MHV-68 is oncogenic (although 
more weakly so than several of the 
  human γ-herpesviruses). Virus-specifi  c 
CD4+ T cells, but not CD8+ T cells, 
have been shown to eliminate tumors 
that were induced by injection of a 
MHV-68–infected B cell lymphoma 
cell line into T cell–defi  cient  (nude) 
mice (2). After adoptive transfer of 
both CD4+ and CD8+ T cells, tumor-
  infi  ltrating lymphocytes were found to 
be primarily CD4 positive. More re-
cently, CD4+ T cell–mediated immune 
control of MHV-68 has been shown to 
be independent of B cells (in addition to 
CD8+ T cells) (3).
There is also in vitro evidence that 
the human γ-herpesvirus Epstein Barr 
virus (EBV) and its malignant conse-
quences are controlled by CD4+ T 
cells. EBV establishes persistent infec-
tion in more than 90% of the human 
adult population and is associated with 
tumors of epithelial and B cell origin, 
which fortunately develop in less than 
10 per 100,000 individuals annually in 
most populations. Usually EBV-trans-
formed B cells cannot grow out from 
peripheral blood mononuclear cells 
(PBMCs) of healthy EBV carriers unless 
the cultures are subject to immune sup-
pression, for example, with cyclospo-
rine A, which indicates that these 
individuals harbor immune cells that 
can target EBV-transformed B cells. 
Depletion of CD4+ T cells abolished 
this immune control (4), and addition 
of CD4+ T cells to T cell–depleted, 
EBV-infected PBMCs inhibited B cell 
transformation by EBV more effi   ciently 
than unsorted T cells. In agreement 
with this initial study, CD4+ T cell 
clones specifi  c for nuclear antigen 1 or 
2 of EBV (EBNA1 and EBNA2) were 
found to inhibit outgrowth of EBV-
transformed B cells (5, 6). These studies 
suggest that memory CD4+ T cells 
specifi  c for EBV antigens can control 
B cell transformation by EBV.
B cell transformation by EBV can 
also be inhibited by EBV-specifi  c CD4+ 
T cells derived from the purifi  ed CD4+ 
T cells of EBV seronegative donors that 
were primed in vitro by dendritic cells 
(DCs) (7). Control over transformed la-
tently infected B cells was evident in 
these cultures after 12 days, i.e., with 
the slow kinetics typical for primary 
immune responses.
Together these fi  ndings show that 
EBV infection in vitro can be controlled 
by virus-specifi  c CD4+ T cells primed 
in vitro (i.e., a primary response) and 
by virus-specifi  c  CD4+ memory cells 
primed in vivo (i.e., a secondary re-
sponse). It appears that this control can 
be exerted by CD4+ T cells directly, 
independent of CD8+ eff  ector  cells, 
which suggests that CD4+ T cells can 
mediate virus-specifi  c immune control 
as eff  ectors in their own right.
Virus-specifi  c CD4+ T cells 
have cytolytic functions
Although it is widely accepted that 
CD4+ T cells provide helper functions 
for antigen-presenting cells and can re-
strict viral replication by secreting cyto-
kines (1), there is also data that 
virus-specifi  c CD4+ T cells can directly 
kill infected cells. EBV-specifi  c  cells 
were among the fi  rst CD4+ cytolytic T 
lymphocytes (CTLs) to be isolated, 
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lymphoblastoid cell lines (LCLs), as tar-
gets. The initial EBV-specifi  c  CD4+ 
CTLs to be studied were clones derived 
from healthy donors’ PBMCs after pro-
longed in vitro expansion with LCLs 
(8), and therefore, there was the possi-
bility that these had acquired cytolytic 
behavior in culture. However, subse-
quent studies described CD4+ CTLs in 
PBMCs without the need for prolonged 
in vitro expansion. These CD4+ CTLs 
recognized a variety of diff  erent EBV 
proteins expressed in both latent—
EBNA1 (9), EBNA2 (10), EBNA3C 
(10), and latent membrane protein 2 
(LMP2) (11)—and lytic—BHRF1 (12), 
BALF4, and BLLF1 (13)—stages of 
EBV infection. Apoptosis induced by 
the ligand of the death receptor Fas 
(FasL) (5, 9) and killing by the death ef-
fector molecule perforin (11) were both 
identifi   ed as cytotoxic mechanisms of 
EBV-specifi  c  CD4+ CTLs. Interest-
ingly, the EBNA1-specifi  c CD4+ CTLs 
and the BLLF1-and BALF4-specifi  c 
CD4+ CTLs described in this issue were 
found to target Burkitt’s lymphoma, an 
EBV-associated B cell lymphoma which 
resists recognition by CD8+ T cells due 
to down-regulation of the MHC class  I 
antigen processing machinery. There-
fore, particularly in humans where 
nearly all tissues can express MHC class 
II molecules after immune activation, 
virus-specifi  c CD4+ CTL could fi  ll the 
gap left by viral immune escape from 
CD8+ CTL recognition.
The presence of CD4+ CTL is nei-
ther rare nor exclusive to EBV immu-
nity and to in vitro–cultured T cell lines. 
For example, in mice infected with the 
murine lymphocytic choriomeningitis 
virus (LCMV), killing by CD4+ CTLs 
was observed in vivo after injection of 
fl   uorescent-labeled target cells coated 
with viral peptides (14). This LCMV-
specifi  c CD4+ T cell cytotoxicity was 
at least in part due to FasL-induced 
apoptosis. In addition, human periph-
eral blood contains CD4+ T cells that 
are positive for the cytotoxic eff  ector 
molecules perforin and granzyme (15). 
These CD4+ CTL are fully diff  erenti-
ated eff  ector cells and some are specifi  c 
for the β-herpesvirus human cytomega-
lovirus (HCMV). Therefore, cytotoxic 
CD4+ T cells have now been reported 
in vitro and in vivo.
Antigen processing pathways that lead 
to CD4+ T cell recognition 
of virus-infected cells
The new concept of direct immune 
control by CD4+ CTL raises questions 
on the pathways that lead to presenta-
tion of viral antigens on MHC class II 
molecules by target cells. Classically, 
MHC class II molecules display pep-
tides processed from extracellular anti-
gens after endocytosis. However, for 
CD4+ T cell recognition of virus-
  infected cells, both exogenous and en-
dogenous pathways for peptide loading 
of MHC class II molecules have been 
described (Fig. 1). Uptake of virus par-
ticles or fragments of infected cells has 
been found to mediate CD4+ T cell 
recognition of EBV-associated tumor 
cell lines. The early lytic EBV antigen 
BHRF1 elicited CD4+ T cell– mediated 
cytolysis of EBV-transformed B cells 
(16). MHC class II presentation of 
BHRF1 was most likely due to uptake 
of antigen-containing fragments (Fig. 
1, pathway 1) from the few LCLs 
where EBV spontaneously entered 
lytic replication (typically less than 
5%). However, the cytolysis was only 
moderately eff  ective (40–80% of LCLs 
were killed), and 21 days were required 
for antigen transfer. CD4+-mediated 
lysis that is much more effi   cient with 
respect to processing kinetics and re-
quired antigen amount is reported by 
Adhikary et al. in this issue (p. 995), 
who examined targeting of the late 
lytic EBV antigens and envelope pro-
teins BLLF1 and BALF4 (13). Transfer 
of less than 1 EBV virion per target cell 
was suffi     cient to trigger IFNγ secre-
tion by BLLF1-and BALF4-specifi  c 
CD4+ T cells as early as 12 hours after 
infection. EBV virion uptake for this 
MHC class II presentation was medi-
ated by the interaction of BLLF1 with 
the B cell surface receptor CD21 (Fig. 
1, pathway 4). Presentation of trans-
ferred BLLF1 and BALF4 even led to 
lysis of Burkitt’s lymphoma cell lines, 
an EBV-associated malignancy that 
can support higher levels of lytic repli-
cation than LCLs in vitro and might, 
therefore, be especially well targeted 
via this pathway.
In addition to these exogenous 
pathways for MHC class II presentation 
of viral antigens from infected cells, ef-
fi   cient sensitization of virally infected 
cells for CD4+ T cell recognition and 
killing has also been demonstrated after 
intracellular transport of viral antigens. 
Endogenous pathways for presentation 
of viral antigens include co-migration 
of viral membrane proteins with MHC 
class II molecules to MHC class II load-
ing compartments (MIICs) via the se-
cretory pathway (Fig. 1, pathway 2). 
Two prominent examples of viral pro-
teins following the secretory pathway 
to intersect with MIICs are the HCMV 
envelope protein gB (17) and the infl  u-
enza envelope protein hemagglutinin 
(HA) (18). Glial, epithelial, and endo-
thelial cells were shown to present low 
levels of HCMV gB to cytolytic CD4+ 
T cells (17). Similarly, mutated infl  u-
enza HA, which was retained in the 
Golgi apparatus, sensitized human lym-
phoblastoid cells to killing by CD4+ 
T cells after processing of HA through 
the secretory pathway (18). Later, it was 
proposed that association of HA with 
MHC class II molecules directs HA from 
the Golgi apparatus to the MIIC for effi   -
cient MHC class II loading. However, it 
remains unclear how effi   cient this path-
way is since most cells block MHC class 
II loading in the endoplasmic reticulum 
by the invariant chain (19).
The second endogenous MHC class 
II antigen processing pathway that has 
been shown to elicit CD4+ T cell rec-
ognition of virus-infected cells involves 
macroautophagy. During this degrada-
tion pathway, the cell engulfs its own 
cytoplasm by forming autophagosomes, 
which are then transported to lysosomes. 
The nuclear EBV antigen EBNA1 was 
found to accumulate in autophago-
somes after inhibition of lysosomal deg-
radation, and EBNA1-specifi  c CD4+ T 
cell recognition of EBV-transformed B 
cells could be down-regulated by phar-
macological or siRNA-mediated inhi-
bition of macroautophagy (20).
Together, these experiments show 
that cytosolic, nuclear, and membrane-
bound viral antigens can sensitize cells COMMENTARY
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for CD4+ T cell–mediated cytolysis in 
vitro. Whether these endogenous and 
exogenous antigen presentation path-
ways contribute to the immune control 
of infections and tumors in vivo re-
mains to be established.
Vaccines should induce both helper 
and cytolytic virus-specifi  c CD4+ T cells
The discovery of a cytolytic eff  ec-
tor function of virus-specifi  c CD4+ T 
cells indicates that CD4+ T cells can 
do more than simply help other lym-
phocytes. Cytolytic CD4+ T cells have 
been targeted in recent approaches to 
rational vaccine design, a good exam-
ple being the development of vaccines 
specifi  c for EBV. Earlier immunization 
attempts focused on inducing CD8+ 
CTLs against the viral antigens pres-
ent in EBV-associated malignancies, 
for example LMP2, which is expressed 
in nasopharyngeal carcinomas (NPCs). 
DCs pulsed with CD8+ T cell epitopes 
of LMP2 were injected into inguinal 
lymph nodes of NPC patients, where 
they induced detectable but transient 
LMP2-specifi  c  CD8+ CTLs. Unfor-
tunately, as with other antitumor vac-
cines that have focused solely on the 
induction of CD8+ T cells, the epit-
ope-specifi  c responses were either too 
weak or too transient to achieve clinical 
responses (21). Since CD4+ T cells are 
necessary to maintain protective CD8+ 
T cell immunity and can target infected 
cells directly, more recent vaccine at-
tempts against EBV-associated tumors 
have focused on inducing both CD4+ 
and CD8+ T cells. NPC cells also ex-
press EBNA1, which is a strong im-
munogen for CD4+ T cells in healthy 
EBV carriers. To achieve simultaneous 
stimulation of CD4+ and CD8+ T cells 
against NPC, a modifi  ed vaccinia virus 
vector encoding a fusion between the 
CD4+ T cell epitope-rich C-terminal 
domain of EBNA1 and the full-length 
LMP2 protein was constructed. DCs 
infected with this vector were able to 
reactivate both LMP2-specifi  c  CD8+ 
and EBNA1-specifi  c CD4+ T cell re-
sponses from blood of healthy virus 
carriers in vitro (22). Furthermore, in 
order to directly target viral epitopes to 
the MIIC, a polyepitope protein incor-
porating multiple class II–restricted vi-
ral epitopes of EBV, including EBNA1 
peptides, was fused to the lysosomal-
targeting sequence of the lysosome-
  associated membrane protein, LAMP1. 
When the gene encoding this fusion 
protein was delivered to PBMCs with 
recombinant vaccinia viruses, activa-
tion of virus-specifi  c  CD4+ memory 
CTLs was observed (23). Stimulation 
of CD4+ CTLs against EBV-infected 
tumors is crucial especially for Burkitt’s 
lymphoma, where EBNA1 is the only 
viral protein expressed and MHC class 
I antigen presentation for CD8+ T cell 
recognition is severely impaired. How-
ever, the work presented by Adhikary 
et al. (13) shows that vaccines against 
Burkitt’s lymphoma and other EBV-
  associated malignancies should stimulate 
not only EBNA1-specifi  c CD4+ CTLs, 
but also BLLF1-and BALF4-glyco-
protein–specifi  c CD4+ CTLs. Indeed, 
vaccination with BLLF1 encoding re-
combinant vaccinia viruses protected 
cottontop tamarins from lethal EBV 
challenge, and part of this protection 
might have been due to BLLF1-specifi  c 
CD4+ CTL (24).
Whether any of the therapeutic im-
munization approaches that have stim-
ulated CD4+ CTLs in vitro will work 
in vivo remains to be seen. One caveat 
of the current vaccine approaches is 
that, although many of them use DCs 
to stimulate T cells in vitro, they do not 
target DCs in vivo. Novel immuniza-
tion approaches (25) that target antigens 
directly to endocytic receptors of DCs 
in vivo promise to achieve a more ro-
bust stimulation of CD4+ CTLs, which 
in turn might lead to a direct attack on 
infected cells as well as effi   cient estab-
lishment of T cell memory.
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Figure 1.  Exogenous and endogenous MHC class II antigen processing pathways lead to 
direct recognition of virus-infected cells by CD4+ T cells. Uptake of infected cell fragments 
(1) or virions (4) leads to MHC class II presentation of viral antigens. In addition, viral envelope as 
well as cytosolic or nuclear antigens reach the MIIC via the secretory pathway from the endoplasmic 
reticulum (ER) (2) or after macroautophagy of cytoplasm (3), respectively. After transport to the cell 
surface, the complexes of MHC class II molecules and viral antigen fragments are recognized by 
CD4+ T cells, which then either secrete IFNγ to restrict viral replication or kill the infected cell via 
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